Key result
Combined high CRP and troponin linked to ~7-fold higher 30-day mortality.
Why the study?
Routine simultaneous measurement of CRP and cardiac troponin in STEMI is not widely used, and identifying patients prone to an elevated inflammatory response remained uncharacterized.
Does an elevated inflammatory response (assessed by combined CRP and troponin test) predict worse short- and long-term mortality in STEMI patients?
Cohort (n=1,186)
No
Does an elevated inflammatory response (assessed by combined CRP and troponin test) predict worse short- and long-term mortality in STEMI patients?
Answers are grounded in this paper and cite their sources.
Simultaneous serial assessment of CRP and troponin early after STEMI identifies a high-risk inflammatory-prone phenotype associated with markedly increased short- and long-term mortality, potentially highlighting candidates for anti-inflammatory therapies.
Elevated concentrations of C-reactive protein (CRP) early during an acute coronary syndrome (ACS) may reflect the magnitude of the inflammatory response to myocardial damage and are associated with worse outcome. However, the routine measurement of both CRP and cardiac troponin simultaneously in the setting of ST-segment myocardial infarction (STEMI) is not used broadly. Here, we sought to identify and characterize individuals who are prone to an elevated inflammatory response following STEMI by using a combined CRP and troponin test (CTT) and determine their short- and long-term outcome. We retrospectively examined 1186 patients with the diagnosis of acute STEMI, who had at least two successive measurements of combined CRP and cardiac troponin (up to 6 h apart), all within the first 48 h of admission. We used Chi-Square Automatic Interaction Detector (CHAID) tree analysis to determine which parameters, timing (baseline vs. serial measurements), and cut-offs should be used to predict mortality. Patients with high CRP concentrations (above 90th percentile, >33 mg/L) had higher 30 day and all-cause mortality rates compared to the rest of the cohort, regardless of their troponin test status (above or below 118,000 ng/L); 14.4% vs. 2.7%, p < 0.01. Furthermore, patients with both high CRP and high troponin levels on their second measurement had the highest 30-day mortality rates compared to the rest of the cohort; 21.4% vs. 3.7%, p < 0.01. These patients also had the highest all-cause mortality rates after a median follow-up of 4.5 years compared to the rest of the cohort; 42.9% vs. 12.7%, p < 0.01. In conclusion, serial measurements of both CRP and cardiac troponin might detect patients at increased risk for short-and long-term mortality following STEMI. We suggest the future use of the combined CTT as a potential early marker for inflammatory-prone patients with worse outcomes following ACS. This sub-type of patients might benefit from early anti-inflammatory therapy such as colchicine and anti-interleukin-1ß agents.
No takes yet. Share an insight, caveat, or question.
Brzezinski et al. (2022) conducted a cohort in STEMI (n=1,186). High CRP (>33 mg/L) and high cardiac troponin (>118,000 ng/L) on second measurement vs. The rest of the cohort (lower CRP and/or lower troponin) was evaluated on 30-day mortality (OR 6.98, 95% CI 1.4-35.5, p=0.02). Patients with combined high CRP and high troponin on their second measurement had a higher risk of 30-day mortality compared to the rest of the cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: